62
Views
0
CrossRef citations to date
0
Altmetric
Notes

Beliefs and Attitudes about Vermont’s Buprenorphine Decriminalization Law among Clinicians Who Prescribe Buprenorphine

, , , &

References

  • Bazazi, A. R., Yokell, M., Fu, J. J., Rich, J. D., & Zaller, N. D. (2011). Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. Journal of Addiction Medicine, 5(3), 175–180. https://doi.org/10.1097/ADM.0b013e3182034e31
  • Beetham, T., Saloner, B., Wakeman, S. E., Gaye, M., & Barnett, M. L. (2019). Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality. Annals of Internal Medicine, 171(1), 1–9. https://doi.org/10.7326/M18-3457
  • Fox, A. D., Chamberlain, A., Sohler, N. L., Frost, T., & Cunningham, C. O. (2015). Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. Journal of Substance Abuse Treatment, 48(1), 112–116. https://doi.org/10.1016/j.jsat.2014.07.015
  • Genberg, B. L., Gillespie, M., Schuster, C. R., Johanson, C.-E., Astemborski, J., Kirk, G. D., Vlahov, D., & Mehta, S. H. (2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addictive Behaviors, 38(12), 2868–2873. https://doi.org/10.1016/j.addbeh.2013.08.008
  • Huhn, A. S., & Dunn, K. E. (2017). Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment, 78, 1–7. https://doi.org/10.1016/j.jsat.2017.04.005
  • Johanson, C.-E., Arfken, C. L., di Menza, S., & Schuster, C. R. (2012). Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug and Alcohol Dependence, 120(1–3), 190–195. https://doi.org/10.1016/j.drugalcdep.2011.07.019
  • Johnson, B., & Richert, T. (2019). Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: Lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. Harm Reduction Journal, 16(1), 31. https://doi.org/10.1186/s12954-019-0301-y
  • Lanham, H. J., Papac, J., Olmos, D. I., Heydemann, E. L., Simonetti, N., Schmidt, S., & Potter, J. S. (2022). Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the Drug Addiction Treatment Act of 2000 Waiver. JAMA Network Open, 5(5), e2212419. https://doi.org/10.1001/jamanetworkopen.2022.12419
  • Louie, D. L., Assefa, M. T., & McGovern, M. P. (2019). Attitudes of primary care physicians toward prescribing buprenorphine: A narrative review. BMC Family Practice, 20(1), 157. https://doi.org/10.1186/s12875-019-1047-z
  • Mauro, P. M., Gutkind, S., Annunziato, E. M., & Samples, H. (2022). Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Network Open, 5(3), e223821. https://doi.org/10.1001/jamanetworkopen.2022.3821
  • Meiselbach, M. K., Drake, C., Saloner, B., Zhu, J. M., Stein, B. D., & Polsky, D. (2022). Medicaid managed care: Access to primary care providers who prescribe buprenorphine. Health Affairs, 41(6), 901–910. https://doi.org/10.1377/hlthaff.2021.01719
  • Monte, A. A., Mandell, T., Wilford, B. B., Tennyson, J., & Boyer, E. W. (2009). Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. Journal of Addictive Diseases, 28(3), 226–231. https://doi.org/10.1080/10550880903014767
  • Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. (2021, April 28). Federal Register. https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder.
  • Schuman-Olivier, Z., Connery, H., Griffin, M. L., Wyatt, S. A., Wartenberg, A. A., Borodovsky, J., Renner, J. A., Jr., & Weiss, R. D. (2013). Clinician beliefs and attitudes about buprenorphine/naloxone diversion. The American Journal on Addictions, 22(6), 574–580. https://doi.org/10.1111/j.1521-0391.2013.12024.x
  • U.S. Drug Enforcement Administration, Diversion Control Division. (2021). National forensic laboratory information system: NFLIS-drug 2020 annual report. https://www.nflis.deadiversion.usdoj.gov/publicationsRedesign.xhtml.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.